Want to see SE:LXB full AI Analyst Report?
Top Page
Luxbright AB
(LXB)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr0.04
▼(-91.25% Downside)
Action:Reiterated
Date:10/01/26
The score is held down primarily by weak financial performance driven by persistent operating losses and sustained operating cash burn, despite improving revenue momentum and a low-debt balance sheet. Technicals are also a meaningful drag, with the stock trading well below key moving averages and negative MACD, even though momentum indicators are oversold. Valuation contributes only modestly because the negative P/E reflects unprofitable operations and no dividend yield is available.
Positive Factors
Low leverage
Minimal debt and substantial equity provide a financial cushion while the company develops and commercializes its products. This reduces balance-sheet pressure and preserves flexibility to fund operations, pursue customer opportunities, or absorb setbacks over the next several quarters.
Negative Factors
Persistent operating losses
Persistent net losses show that current commercial activity has not yet translated into a profitable operating model. Continued losses can consume the company’s equity cushion, limit internally funded investment, and make progress toward sustainable earnings dependent on materially better margins or revenue scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Minimal debt and substantial equity provide a financial cushion while the company develops and commercializes its products. This reduces balance-sheet pressure and preserves flexibility to fund operations, pursue customer opportunities, or absorb setbacks over the next several quarters.
Read all positive factors
Luxbright AB (LXB) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr10.17M
Dividend YieldN/A
Average Volume (3M)903.10K
Price to Earnings (P/E)―
Beta (1Y)-0.58
Revenue Growth-13.46%
EPS Growth4.75%
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.16
Shares Outstanding242,242,220
10 Day Avg. Volume724,373
30 Day Avg. Volume903,096
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.09
Price to Sales (P/S)4.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr17.50M
Luxbright AB Business Overview & Revenue Model
Company Description
Luxbright AB (publ), a technology-driven enterprise headquartered in Gothenburg, Sweden, specializes in engineering and marketing X-ray tubes, generators, and comprehensive X-ray systems. Established in 2012, the company's primary focus is on prov...
How the Company Makes Money
Luxbright AB’s revenue model is based on monetizing its X-ray source technology through sales and commercialization of products and related offerings. The primary revenue stream is expected to be direct revenue from delivering X-ray sources and/or...
Luxbright AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.35M | 11.41M | 9.02M | 854.70K | 811.70K | 729.00K |
| Gross Profit | -38.22M | -21.37M | 8.88M | -2.80M | 189.12K | 1.98M |
| EBITDA | -19.23M | -16.76M | -15.72M | -23.87M | -20.47M | -17.63M |
| Net Income | -21.51M | -19.46M | -17.72M | -25.38M | -21.13M | -18.10M |
Balance Sheet | ||||||
| Total Assets | 32.25M | 39.38M | 42.66M | 40.69M | 31.19M | 23.99M |
| Cash, Cash Equivalents and Short-Term Investments | 362.00K | 5.29M | 12.36M | 14.04M | 7.60M | 7.51M |
| Total Debt | 3.24M | 4.56M | 254.19K | 206.02K | 588.34K | 1.10M |
| Total Liabilities | 8.85M | 12.49M | 8.46M | 7.00M | 3.33M | 3.36M |
| Stockholders Equity | 23.41M | 26.89M | 34.20M | 33.69M | 27.86M | 20.63M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Operating Cash Flow | -20.93M | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Investing Cash Flow | -2.92M | -3.65M | -3.44M | -3.99M | -7.15M | -4.15M |
| Financing Cash Flow | 7.89M | 16.46M | 18.28M | 30.82M | 27.88M | -708.00K |
Luxbright AB Technical Analysis
Negative
0.48
Price Trends
0.06
Negative
0.09
Negative
0.22
Negative
Market Momentum
>-0.01
Negative
41.50
Neutral
51.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LXB, the sentiment is Negative. The current price of 0.48 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.06, and above the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.50 is Neutral, neither overbought nor oversold. The STOCH value of 51.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LXB.
Luxbright AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | kr1.55B | -305.68 | -1.22% | ― | 34.05% | -144.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr543.18M | -64.17 | -2.84% | ― | -13.72% | 52.47% | |
45 Neutral | kr43.83M | -4.90 | ― | ― | -19.44% | -475.48% | |
44 Neutral | kr10.17M | -0.28 | -85.54% | ― | -13.46% | 4.75% | |
41 Neutral | kr208.08M | -0.93 | -303.61% | ― | 51.21% | 42.24% | |
41 Neutral | kr26.39M | -0.15 | -57.15% | ― | ― | 16.02% |
* Healthcare Sector Average
SE:LXB
Luxbright AB
0.04
-0.69
-94.11%
SE:PAX
Paxman AB
66.70
-1.30
-1.91%
SE:SCIB
SciBase Holding AB
14.85
-13.52
-47.65%
SE:SPEC
SpectraCure AB
0.02
-0.13
-88.28%
SE:BACTI.B
Bactiguard Holding AB
15.40
-4.60
-23.00%
SE:SDOS
ScandiDos AB
0.60
-0.51
-45.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.